- Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia - cardiovascular complications and bleeding2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Research Report University Hospital for clinical evaluation of PCI-32765MCL3002Publication without faculty affiliation
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)2021 | Faculty of Medicine in Hradec Králové
- Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells2020 | First Faculty of Medicine, Second Faculty of Medicine
- A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study2020 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia2023 | Faculty of Medicine in Hradec Králové
- The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT2023 | Publication without faculty affiliation
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus2020 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial2020 | First Faculty of Medicine
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial2023 | Faculty of Medicine in Hradec Králové